<SEC-DOCUMENT>0001193125-14-021166.txt : 20140127
<SEC-HEADER>0001193125-14-021166.hdr.sgml : 20140127
<ACCEPTANCE-DATETIME>20140127080052
ACCESSION NUMBER:		0001193125-14-021166
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20140127
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140127
DATE AS OF CHANGE:		20140127

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GALECTIN THERAPEUTICS INC
		CENTRAL INDEX KEY:			0001133416
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				043562325
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31791
		FILM NUMBER:		14547425

	BUSINESS ADDRESS:	
		STREET 1:		4960 PEACHTREE INDUSTRIAL BOULEVARD
		CITY:			NORCROSS
		STATE:			GA
		ZIP:			30071
		BUSINESS PHONE:		678-620-3186

	MAIL ADDRESS:	
		STREET 1:		4960 PEACHTREE INDUSTRIAL BOULEVARD
		CITY:			NORCROSS
		STATE:			GA
		ZIP:			30071

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PRO PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20010612
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d663089d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT
TO SECTION 13 OR 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>OF THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): January&nbsp;27, 2014 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>GALECTIN THERAPEUTICS INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Nevada</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>001-31791</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>04-3562325</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>4960 PEACHTREE INDUSTRIAL BOULEVARD, Ste 240 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NORCROSS, GA 30071</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) (zip code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: (678)&nbsp;620-3186 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or
former address, if changed since last report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Check the
appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17&nbsp;CFR 240.14d-2(b))
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17&nbsp;CFR
240.13e-4(c)) </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;8 &#150; OTHER ITEMS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;8.01 Other Items. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
January&nbsp;27, 2014, Galectin Therapeutics&nbsp;Inc. (the &#147;Company) issued the attached press release. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SECTION&nbsp;9 &#150; FINANCIAL
STATEMENTS AND EXHIBITS</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01 Financial Statements and Exhibits. </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="96%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(a) Financial Statements of Businesses Acquired.</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Not applicable.</P></TD></TR>
<TR>
<TD HEIGHT="8"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(b) Pro Forma Financial Information.</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Not applicable.</P></TD></TR>
<TR>
<TD HEIGHT="8"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(c) Shell Company Transactions.</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:4.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Not applicable.</P></TD></TR>
<TR>
<TD HEIGHT="8"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(d) Exhibits.</P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="96%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:26.20pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit<BR>Number</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">Description</P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP ALIGN="center">99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release dated January 27, 2014</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 2 - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, Galectin Therapeutics Inc. has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="41%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3">Galectin Therapeutics Inc.</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date: January&nbsp;27, 2014</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jack W. Callicutt</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Jack W. Callicutt</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 3 - </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d663089dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g663089g48c01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Galectin Therapeutics Inc. and SBH Sciences, Inc. Announce the Formation of </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Galectin Sciences, LLC, a Collaborative Venture to Research and Develop </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Galectin Inhibitors for Oral Administration </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NORCROSS, Ga., and NATICK, Mass. (January 27, 2014) &#150; </B>Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target
galectin proteins to treat fibrosis and cancer, and SBH Sciences, Inc. , a world leader in cell-based assays to measure biological activity and developer of cytokines, growth factors, biologics and monoclonal antibodies, jointly announce the
establishment and formation of Galectin Sciences, LLC, a collaborative venture to research and develop small organic molecule inhibitors of galectin-3 for oral administration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Using computer molecular modeling techniques coupled with <I>in vitro</I> screening of a variety of compound libraries, SBH Sciences recently identified
several small organic molecules with promising galectin-3 inhibitory activity <I>in vitro</I>. Galectins, a class of proteins made by many cells in the body, are known to be markedly increased in a number of diseases including scaring of organs and
cancers of many kinds. Galectin Sciences, a Georgia-based LLC jointly owned by Galectin Therapeutics and SBH Sciences, will allow the companies to collaborate in further development of these unique organic molecule inhibitors of galectin-3 as drug
candidates as well as discovery of additional candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Galectin Sciences will build on the scientific body of knowledge amassed by SBH Sciences,
coupled with Galectin Therapeutics&#146; knowledge and expertise of galectins&#146; pathological role and mechanism of action in inflammation, fibrosis and many cancers. The long-term goal of this effort is to identify and develop drug candidates
that are highly specific galectin inhibitors which may be formulated for oral administration. The intermediate term goal is the development of small molecule inhibitors of galectin-3 which exhibit activity in <I>in vivo</I> preclinical disease
models of fibrosis and cancer in which galectins play a key role. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Raphael Nir, President and Chief Science Officer, SBH Sciences, said: &#147;We
are excited and honored to partner with Galectin Therapeutics, a company that we have provided services for more than 10 years.&nbsp;This unique moment is a transformational point for SBH Sciences and represents the shift in our business model from
service provider to biotechnology company. Targeting of galectin-3 by small organic compounds is a unique opportunity to resolve&nbsp;significant&nbsp;unmet medical needs,&nbsp;and Galectin Therapeutics is the ideal partner. I am confident that the
mutual trust and the dedication of the two teams, combined with the vast expertise that has been built by SBH Sciences over the past 16 years, will enable us to potentially bring new galectin inhibitors into clinical development and human clinical
trials.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Galectin Therapeutics has a long standing interest in compounds that bind galectins, particularly galectin-3, which has resulted in two
clinical development programs involving intravenous administration of the company&#146;s proprietary galectin inhibitor compounds GM-CT-01 and GR-MD-02. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 1 of 3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Galectin Therapeutics is pursuing synthetic routes to newer large molecular weight carbohydrate entities as well as smaller carbohydrates which might be administered by alternate routes. Longer
term, the company is also interested in developing small molecule inhibitors of galectin which may be orally active. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;The formation of Galectin
Sciences represents a significant step forward in the research of galectin proteins and demonstrates both companies&#146; confidence in galectin inhibitors as potential treatment options for diseases with large unmet medical need,&#148; said
Dr.&nbsp;Peter&nbsp;G. Traber, President, Chief Executive Officer and Chief Medical Officer, Galectin Therapeutics. &#147;Increased levels of galectin proteins have been implicated in a very large number of inflammatory, fibrotic and neoplastic
diseases; the discovery and development of orally active galectin inhibitors would be a major step towards expanded treatment approaches for these disorders. This work may lead to drugs that would expand our pipeline as follow on compounds to our
first in class galectin inhibitors, GR-MD-02 and GM-CT-01, which are currently in clinical trials.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Galectin Sciences, LLC </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Galectin Sciences, a Georgia-based LLC, is a collaborative venture to research and develop small organic molecule inhibitors of galectin-3 for oral
administration. The venture, jointly owned by Norcross, Ga.-based Galectin Therapeutics, and Natick, Mass.-based SBH Sciences, was formed based on the scientific understanding of the role that galectin proteins play in a number of diseases including
scaring of organs and cancers of many kinds. Galectin Sciences seeks to identify and develop unique organic molecule inhibitors of galectin-3 as drug candidates which may be formulated for oral administration in the treatment of certain human
diseases. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Galectin Therapeutics </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Galectin
Therapeutics (Nasdaq:GALT) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company&#146;s unique understanding of galectin proteins, key mediators of biologic function. We are
leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and
commercialization for our lead compounds in liver fibrosis and cancer. Additional information is available at <U>www.galectintherapeutics.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About SBH Sciences, Inc. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SBH Sciences, Inc., located in
Natick, Mass., and founded in 1997, is a biotechnology company and&nbsp;a&nbsp;preclinical Contract Research Organization.&nbsp;SBH Sciences has provided research products and services&nbsp;to over 120 pharmaceutical, biotechnology, and diagnostic
clients&nbsp;across the globe, mainly in the fields of oncology and inflammation.&nbsp;SBH Sciences specializes in lead drug optimization through innovative cell based cytokine bioassays, biomarker profiling, and&nbsp;customized&nbsp;analytical
method development including multiplex analysis.&nbsp;SBH Sciences is the world leader in cell-based assays and currently offers over 280 validated assays and 300 cell lines to evaluate biological activity of lead drugs, cytokines, growth factors,
and other biologics. SBH Sciences&#146; proprietary processes have been utilized in commercial production of 31 cytokines, 9 recombinant Glycosyltransferase enzymes, 31 monoclonal antibodies and over 30 ELISA kits. In the last 3 years,&nbsp;SBH
Sciences&nbsp;has assisted three biotechnology companies in advancing their lead compounds into phase I clinical trials. For further information, please see&nbsp;<U>www.sbhsciences.com</U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 2 of 3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform
Act of 1995. These statements relate to future events or future financial performance, and use words such as &#147;may,&#148; &#147;estimate,&#148; &#147;could,&#148; &#147;expect&#148; and others. They are based on current expectations and are
subject to factors and uncertainties which could cause actual results to differ materially from those described in the statements. These statements include those regarding the potential benefits of Galectin Sciences, LLC, or any drugs or treatments
developed by Galectin Sciences, LLC or its parent companies, the potential to bring new galectin inhibitors into clinical development and human clinical trials, the promising nature of any studies or research, current, intermediate-term and
long-term goals related to the new collaborative venture and/or Galectin Therapeutics, potential treatment options, research and development plans and the possibility of an expanded pipeline with new drugs or treatments. Factors that could cause
actual performance to differ materially from those discussed in the forward-looking statements include, among others, that plans, expectations and goals regarding any research and development activities, preclinical data and potential therapeutic
uses and benefits of any drugs and any future pre-clinical or clinical studies are subject to factors beyond the companies&#146; control. Future research efforts including preclinical or clinical studies may not begin or produce positive results in
a timely fashion, if at all, and could prove time consuming and costly. Plans regarding development, approval and marketing of any drugs are subject to change at any time based on changing needs as determined by management and regulatory agencies.
There is no guarantee that this new collaborative venture will be successful or that it will ultimately lead to meaningful revenue or earnings. Regardless of the results of current or future studies, success may not be achieved in developing
partnerships with other companies or obtaining capital that would allow further development and/or funding for any studies or trials. To date, Galectin Therapeutics has incurred operating losses since its inception, and its ability to successfully
develop and market drugs may be impacted by its ability to manage costs and finance its continuing operations. For a discussion of additional factors impacting Galectin Therapeutics&#146; business, see its Annual Report on Form 10-K for the year
ended December&nbsp;31, 2012, and its subsequent filings with the SEC. You should not place undue reliance on forward-looking statements. Although subsequent events may cause views to change, the companies disclaim any obligation to update
forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CONTACT: Galectin Therapeutics Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Peter G. Traber, MD, 678-620-3186 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">President, CEO,&nbsp;&amp; CMO </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><U>ir@galectintherapeutics.com</U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 3 of 3 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g663089g48c01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g663089g48c01.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`40)0`P$1``(1`0,1`?_$`.8``0`"`04!`0$`````
M```````)"@@$!08'"P(!`P$!```&`P$```````````````$$!08'"`(#"0H0
M```&`0,"`P(&"`X,"PD```$"`P0%!@<`$0@2"2$3"C$405%A<2(5D:'1,E(6
M%SE"DB.S-'1UU3:V=SAX&8'3E+0EM5:6-[<8&L(S0R3457:7*%BX@U0UA96E
M)B=7$0`!`P,#`@,#!@<+"0D````!``(#$00%(1(&,0=!$PA1(A1A<8$R%0F1
ML7(C<[,6H<'10C,TM#5U-SA2LF.3TU1T=A?Q8D,D9)15-AC_V@`,`P$``A$#
M$0`_`+_&B)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)H
MB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(F
MB)HB:(FB)HB:(L'.XMS-@^!?$W)W(B2BRV*<K[%C"4&I=9RJVO(=ME6-6I$&
M4B6RRJ3RSS+0BI2"0PI&'8Q1'J`B@EQ#V/[UW(ZQ!<JN[EFJ_7B_Y1C&=TJ&
M`Z:I5X7'V':K8TBRM=K)#+0,Q..I6-@G2"2XGD5>E3K`P`;P`B[A_P!U'[5'
M^2N1/\X8C]X-%"@3_=1^U1_DKD3_`#AB/W@T2@6U37I9.T;6HQY-V*-M\!#1
MZ)W#^7FKC78J,8H)E$QUWC]]"H-&R)"@(B8YRE``]NB4"QD:=C?TZ+Z>"L-.
M16-%YXRQ6Q8Q/D5B,SDSDYN@C<I`4W,N<X@!2!](1$``/'1*!93M/2I]IV0:
MMGS"O7MZR>().6CQI:(1RU=-ER`HBX;.$8(Z*Z"R9@,4Y1$IBCN`[:)0+AUX
M],QV7,8MF;W),TZQ\SD55$(]U=\G4FJ-WZR0)BJBR6GH]@FZ53!4O45,3&#J
M#</$-$H%U<IV"/3YHG,FMGG'"2A=NI-7D=AU,Y=P`0ZB'7`Q1$!W\0T4:!;M
M">GI[!]F>)QU;R_3K!(*B`),83/N*95XH(B!0!-JP%PN<1,.W@7VZ*%`N\R>
ME*[4JA"J)U?(1R'*4Y#DL<.8AR&`#%,4Q8`0,4P#N`AX"&B4"XM<O3!]G#'4
M,>Q9!<3-%KZ:Q&ZD[<<A5&LPY%U`.9-`\G-1;)D590J9A*43]0@4=@\-$H%\
MTWTPO9NR-$!8,?.9F]0(KJ-0FZ=D.I6:)%RB!#*MPD86+>LQ72*H43$Z^HH&
M#</'1*!<M_W4?M4?Y*Y$_P`X8C]X-$H%U2Z]-]V.&-O)CY[>HYI?5':<>G27
M.8\=H6X[]4PE29%K:K<LR+M4P"!4_)ZS"'@&B4"[5#TI':G$`$*KD,0'Q`0L
M40("`^P0'Z@T2@7[_NH_:H_R5R)_G#$?O!HE`N'73TV5`X]QSO+7;"SOD_C)
MR9J[924JCYTZJDU3+=(QJ9W4;`6UH]JWOQ6#QT7R1.@Z:B0JQA$X>`@45)%V
M@N?MOYPX%M$=FNM(4;D]QZO4MAW/M313<-D`M4(5N\C[#'-':KE=./L5;DF#
MS?SEB"HX'I,`"!0(I:]$7\_-(/@`[C\QON:(H]>2_=@[=_$*WGQQGSE1CFJ9
M/(#41Q7"GF\@Y0W>@8S1,<>X[B+5;2*N2E$2%,T*8P!X!HBX9CCO-=MG)=N@
MJ$RY*1E$N-J?M8RJ5_-]#RA@)Y:G[PQ4VK2MJ9HI5%9S;A=0X%*1NJH<3"``
M&^B*2.3M%;A'$$TF)^'BG5HDRPM:;2,BT9KV&8,Q=298N$2<*IGE9`T<Q67!
M%`%%/)1.?;I*80(MZ\U/\+[1ON:(GFI_A?:-]S1$\U/\+[1ON:(NH,R<AL$<
M=Z^SM>><P8XP[6I%VNPCIS)-P@Z;&2#YLU4?+LF#N=>LDGCQ)FD94R28F."9
M1-ML&B+K_C/S7XJ<R6M\D>+6<J+G.(QE.QU9NTYCY^M-0,//2T<,JQC2SB;8
MD5)+J,`\PPM%5R)_>F$#>&B+)_S4_P`+[1ON:(GFI_A?:-]S1$\U/\+[1ON:
M(GFI_A?:-]S1$\U/\+[1ON:(GFI_A?:-]S1$\U/\+[1ON:(GFI_A?:-]S1$\
MU/\`"^T;[FB)YJ?X7VC?<T1/-3_"^T;[FB)YJ?X7VC?<T1?"CINB0RJRR:*1
M`$QU53`FF0H>(F.H?I(0H?&(@&H$@"IT"Y-:Y[@U@)<>@&I*VX;#`%`3&G(@
MI0#<3#),@``^,1%;8`UU^?#_`);?PA=XLKPF@AEK^0[^!:QM(,7J0+LWC9X@
M81`J[19-RB(A[0!5$QR"(?"&^N;7->*L((^1=4D4L+MDS7,?[""#^`HM(L&Y
MBE</6C<Q_O"N'"2!C_*4JIR"8/FUR76OCZUB_P#K)A_=C?\`MFB)]:Q?_63#
M^[&_]LT1?1)*.4.5--^S44..Q$TW**BAQ^(A"'$QA^0`T1:OK*`"(]0`'M$2
MF^YHB^M$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$
MT1-$5>WU&92J\5N/K=0`.@OS4XFIKHG^DDNG_M%XEW363'<BJ8_"!@$-$4^M
M7332K5=22(1))."B4TTTRE(FFF1@W*0A"%`"D(0H;`````&B+?=$01``$1\`
M#Q$?D#1%0?YV\I,[]Y'O,Q?:CQ]ERTX:XJXDL\XRRN>AR[NN66Y)5&P1E;R"
M9U)1*S1[(I)'$Q6;55P"!RJF$P%T166(_L,]L",Q4IB=GQRC4H]2/,S&W!8;
M*.1RNC)`4)9+(/UK^-R4BFL4%2*%>`)3AX>&B+B7;3X@<V.".<<QX"MF6W.>
M.!'U0G/\>;5D2?DYO,U"FW#F-<N*#(OY)!Z\F:LR+)ODD'#J3<KD39H%*4"B
M(%(H-O6L2LM$X&X<N(B6F(E8;_DPJAXR2>QY%@^KJ*)`5*T<(@N*8[B7K`>@
M1W#VZ(LMNR[VC^`O([MH<7,PY>PLYMV1KI5)Y_:;*_OMY%Y+O6UYM4:@NJ"4
M\D1/RV+)),"E#;8@:(NW>:/IC^'V6Z/-37$Z9R3Q=SS'13M2H6JJY5R.:`>R
MJ3?>.8S<:XLCINQ8J.2$%1PW;G7*`?1`=$4)7I].\IRGPUS/<=KOF];)[(D.
MZG[%3J?;;4]&;M5+N->BW"[:-D+%(*FFIJ*GOJY))'WA98R:CC<`#VZ(IHO5
MM/'S#M2/W,>_?QS@N::87SH]ZY9*F3-7[@)DE#ME4C*)&$H")1$2B(!X:(N,
M>D,D)&2[7*SF3D9&3<&S??P\^2?.GZP%!C6MB$4=JK'(F7?P*`@4/@#10"M2
MZ**\M[DA/V!/U3D#%DL4\G''YD58@L@G)5-J"?U^\,"!4$W/E@@`A_Q>WE[>
M&VVB+U&&?[#:_M9#V^/_`"1=$6IT1-$5;GL\]!>Y!WFDTA*FE_M$T\P-PW+L
M8<(80ZE03`/+`#&$?'??1/%61M$5.GU"O=YS?7LWXN[/?;XGG$-RAY$2]#JN
M5LKUF1<I6/%S/)LRTCJSC^KO(PP.H*TSL8Y+(S$@4P+1T*LF"/2JN91`BG%[
M:W:=XP]MC$L/6*)5HF_YODVH/\O\EKM"QTQEK)]P?&,YG'[JSR"#F8BZX+]4
MX,HU)?RT4"D%45E^M8Y%(%DO%&,,SU*6H67,=TG)=+G6BK&7J]YK$-9H-^V6
M()#$6CY9FZ0ZR@;<AR@51,P`8ABF`!`BJ5Y7X[\A^$G>5[2?&>%RC<L@=NRV
M9]SAF+CI6+R[DK)8L&Y#2PG;H2SX';W>1=N'DMC"JQ,D$E4V3KK7CF\@Y0*H
M8B.YB*XGHB:(FB+'OD_Q]PMR1PY>,?9PQ?0<I5EU4K<FTC[[48*V)0KV1K4E
M''F8+Z[8O#PLTBW7$$W;44G"?Z$X"&B*I9Z*AFG'\8N>#!(1%-CR;JC-,1]H
MIMJ`*)!'VCN)2:(KJ^B)HB:(FB)HB:(NGL6YVQQF6P9HK5`EU9B2P#E-?#.2
MA%L9)I&9!9U"J7=]#LW(F,1^#"$NC$%CEV!-P91(?I)CHBZ4Y_\`+L."W%3)
M7)K\EEKS*:@%@DTZ'4%3-'K]6?G&$&F_DI,L?*C#P$29[Y[QU[LOY21/O?'<
M*3FLG]D8]U]Y;I-I`H-.II4FAH!XFBO;MYP[]O.66W&/BX;(7&\^;)J!L:74
M:VK=SW4HUNX5/BN7<,.20<O^+^'>288[LV*/RL5@U@&@V\14FH`Z4B^C%$S.
MA:,!D(YX=B+AFY\A'WAHJFIT%ZMM=V*OOM*PCO=AC\P5VG6E"1UTJ#2H-.BD
MN:\:_8_E%YQOXB.[^$DV^:S1KJM#NE3M<*T<VIHX$5*R>U4%:R:(FB+!SN9`
MY-V^>8Q&171WBG'[(J3--D"PO57:L(NDV19E;_JYW2RQRE3*3Z9CB`!XCJD9
MZGV//7IL_?"S!Z?_`"QWLXN9=HB&9MB[=3:`'@DFNE`-23H!U4*7:@[$%(QU
M1:?R+YQI/[]DZ=A&MFA\&VIVM^(&+F#QLF]9'O3!RX,6R71LV,"BZ*YBQ\<8
M13,FLH45`I&+X_"]C;J^;J1I'K0?E:ZGQIX+:WU(^L?*Y?+77">TCF6/'K>0
MQR9"*GGW1::.\AX'YJ`G1KQ^<D'O;F-.TR[WGN)\2<'JMZ-4".K6VANIB:.Q
M%`1)*M!^[CY0M&SD[B%A52D$NP>Y^:F'QZNJ***%@CA:UD8\``!^`+S[N[R\
MR%PZ[OY9)[MYJY\CG/>X^TN<22?G*YOCKDKQ)YF,?Q)=)0TC./45@+C[)$0U
M8V)1("[JJ0BXJ+(N5@)]+_F#H5R``F$``-]=BEE#9STXP4_C5<HA2@9&&2BK
M:=TO^3R1FU'5QIA2AYY%U?)5ZW%9=`;H;++E37*8.@?,#Z8$6`GOCW_WY]_=
MKK^VZ(LIN$:BSOEA@]HY<O%FSNVK-G")WCH2*H+P<NDJ0WZL`AU$.(;AL(>T
M!`=$69U][;7+FK(Q%CXJY1:8TR%2>5W(;,]5/9,NY2GJA/8UM<8ZJF&L=WF)
MDI:6/)UNO5:QR1S1I0\EB_1:K$$YB=0$4M?"W#=^X^<7L/X7RA?IG*=\QY7W
MT#8LCV&8?3T[=G)+#,.F]DEY21,=XM(2K!TDJJ0QC`@<PI%$2D`=$64.B)HB
M:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(J]_J+_P":
MYQX_IK<3?_47B71%/M6_X.P'[BQ?]XH:(MZT1?AB@8HE,&X&`2B'Q@(;"'V-
M$7EL=UF!Y-]D_O;3O-F@5ARYJ.1LAS65*A-OF;Y.HW.-M-D1MENH2\DF0&OG
MM3NFZ"Y2BIT#L(D^#1%;#X.^J>[<?*T(*L9)L3[C5DF1,R9NHW)+V-;4L'S@
MH$$&MW?*0K14IU_`"BW`0W`/BW(K)E>L4!;82,LM7F8RPUZ:9H2$1-PSU"1B
MY-@Z3*LV>,7K4ZC=RV72.!B'(82F*.X#HBI&>MF,'^S_`,/2]9P$<@Y)$2>T
MA@^KJ-X^W8!+HBGK]/8F<G:"X9F,&P*4BS&(/Q@&2+H`_;T19M\U.=G''@5A
MZRYBY`Y`@:Q&PD8\>Q5<<2T<VL]N?-FQW"4+6(ITX2<RDDZ`FQ$TBG-N/L'V
M:(O-_P"RQQMY`=R_O(J<T8^B2L'B*`RK.Y>NMY=QS]*N,U&Z"RU=@H^2%JFQ
M?2[YRV:D.B"A3)D6ZQ`0V`2*V!ZN7\T[(_RU4O\`B]<M$76WI$[76(3M;*(R
M]BA8Q<<W7\?=WTBU;+@7W&L;'%-90A@((CX#\.B@%:;)D>@'$`)<ZP83?>@6
M:CQW^;]7\?9HHKR]^0KYD]]5'6WC!VT?M'',2K&2<MG*:K=0IYMX(="Q.HAQ
M\?8&B+U,V?[#:?M9#]:+HBU.B)HBJ#U@>Z=P&YY]P?(>$NWT^Y)XZY*92KET
MJMK2O[^J>2C'XWQS6%T1*GCJT$<I%<557Q!4@`8VVWAXE#Q68^).]KGJB9TQ
M1A/N-<"[]P_C\\6=C2L6Y;)9WMUQVXN4FY;MX^N625=T*F,8)=Y[P)BG,X4,
M!43CT#L.Q%3`[/V47W./U,V/^05_65?RE[SUG7,#8K\H*':C7Z#>GM-CBD+T
M%3)7XZ/9H-PVV2*V)L'T0T45ZL&B)MO[-$72>4N.^*\RW;!60[_7W$I;N-^0
MW^4,2RK:2>QYZ_;96H3U&D7#A-HHFG*,'E>L3A-1JN!D3*`F<0ZDRB!%R_*N
M3*=A;&.0\OY$D_J2AXMI5FR#<I;R3N#Q]9J,.\G9ITDV3_5'2Z3!B<4TB_24
M/L4/$=$4''"?N"<]^[3BRU<D.'U6XZ\5>-;3)%CH.,)OD/"7S,.6\HIU'W1O
M.621JU-FZ)4J3#`_<^0DFE(RJPN$EDQ/^I]1B+;Z?W=<^<=.Y1BOM>=Q3%6*
MVUUY`UV,F^/')CCM,6(F/;X>6<6%A&Q=WQQ=4U9VC2CZ9K;EANA(OTDG7D^!
MT5@6*13YV[^"=JW\!_%J>W#_`.5.]$5-7T7'\W'G[_2GKO\`$931%/\`=Q/N
MA4O@Y:<!X#IN/9+D%S&Y96I&E\>./L#.LJX22=+OD(M:[Y'M+E"1-2L<0[MS
MNN]*S=++E;K^4F)4%U$B+K'.V1.\OQZQ+?>2!HS@IG*.QM4);(%NXR4^)S)1
M[$XK-=C5)FTQ=`S7-RLTWG[/$Q+1<[,']<8HR*J8%Z41,4HD63G;3[C&#NZ#
MQ=K7)S!Z<G",WDF^JMZQ[85V2]JQM?8A-LK+5:;,P.9!XEY#M)RQ>D*1-\R6
M35`A#"=,A%BOEWNOS]SYN3/;>[?6)JUR'Y+T"%/9>0&2LA6Q_4>-W&R#1-')
MJM[K8*Q%6*S7&[>\2B+<(.-10.#L_D*."'3<^01=%\[.>G<K[3^%6G*_DK5^
M+?+G`K2_U6H9*K>":[DS"V2<=1EK6=-F-FA9&U361:Y:(XDFFFS4*\)'"55=
M$>O8YNDBS%Y0<J>4-_[=T;R[[=\+B)JO=N/,WG=*:Y-.K?7)2@4Q;&ZEWB9*
M(I%=K%C:6J[L2E4)]72#IE'"LF01652,)1(J]_IA\T]Q_)7"?D)D[&M+XYYJ
M>9*YIY6O>1LA\@,WY)HE]GLFV2DXRD+&X6BZ?B"^12T8J55!5-?WE$_F*J)@
MB5-,FY%,_P!UCN)<WNWEQHG^0K'@QB/-^-*54J.?+]D)R)<,8RNV"X.F%=GF
M;.B.\;!8;'2X>S2J#4KPRB2SINJ"JC=$H'Z>+FM>TM>`6GJ#T7)CWQN#V$M>
M#4$:$$>(/@5DIVF>9&2.>G;HPERTN=0IM;R!D^,R&[2I=55?1=/8#6+W:ZQ6
M85LZ>_63UHT%A"-DUEQ*H)1$QRI[;$U$`-&UN@"@YQ<XN<27$U)/B5"CR!]0
M?RWX;]SG"7"[FEQ6PQA+%-Q:$M=INN-LBW//-EL%&L4+:V]0=T=)A4:FZ6L+
MBZ5X(\(L(I5V[<F!)(/U1,PQ4%+7D#('>4R[3%LA\9\0\0..T<LQ)-TK%O*B
MR9$N69;?&KM0<Q[*_?DZ8,J/A^=DTA(8T>1U/JQZBGE.5BJ$4*4BZE[-/>/=
M]S%WR-PME_"@<?.6/$BTDJV9:!&3JMDJ$@4T]8*L>:JTF[;-9!N9A8JRZ:O6
M:P+`@84CIN%B*@)2*;Z7AXJ?CG,1.1S.6BG@)E>1T@@FY9NBHK).4B.$%0,F
MJ0BZ)#["&VY0UPDBCF88Y6AT9Z@]/:IBUN[FQG;=6<CXKEE=KFDAPJ"#0C4:
M$A19=UK.=@H.-ZEBNK/W,6]RLM,*V>0:*"BX-3X,C5%W#)JDV433G'TBF182
MB43()')X@<0US4NH'L84"2RED*F8V@W;&-E;K/,J[&O)$%0CFCEZ)BHJNP;$
M47!N3H\>@HC\FB*3N([37(FOR\9/0>6<;1,W"/VTG$2K!S:6SZ.D6:I5FKQH
MX)%`=%=%0H"`A\P^`B&B+5V7M4\EKE/REIMF8\>6*R3;DSR6FY=Y:GDB_<&`
M"^8NX5BA,($*`%(4-B$*`%*```!HBV/^J$SK_P#TG%?Z>S?O3HB[HXZ]LW+^
M'LWXWR?/7O'<E#4R?^MI!A%&GQD7*'N+QKY;0',:BW%7K<@/TS`&P#HBFNT1
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MN>7QGE*'E5A=1K9PN/GDCG!$I`JZ*HJ@54A/+$A`VT123^MF-_X?^'H>8&WY
M0<DCY?2.X_X.HWT@-MMX?/HB[@[.797X\\BNV[Q@S'8LR<CZ]8+K5)V0F(BJ
MWQE%UUFY:WBTQA$HEB:'<G0;G;,2',!CB(J&,/L'1%LW<2])=2LN4J>O7&'D
M5F5?,44R4?Q%/RY:F5CIMG=,FRAD(XG^"VBD;(.URE*145TD"@8>OPV$"+`;
ML1]^7-^`^2=6[:W-2GUN,K@V$<5UJTM*^SK-GI%Q0ZF,1"6$L<#9I)QLM)@@
MBDH=NHN4[GJ,KY8!TD4V_JY!`W:<?F*(&*;--*$I@$!`0&NW(0$!#P$!#1%%
M?Z:SM-<+.9?;V_*MG"DV>>O`9;N$,H]C[W<:\R&.C&L`JT2(P@)^-:]8'<GZ
MS"GU&`0\?#10"L))^GD[9J9B&#%UQ'I`0V'+&3MC`)C'V':W!X`(_!M[-%%4
M-['A+'O'?U+>-,/8LCGT31J;RWJ$7",'TF[E72#9&9<I]!Y"5=/7K@NR8;"H
MJ<^WP[Z*"]81G^PVG[60_6BZ**U.B)HB:(J]OJ7XMH?MR-[25,$I^D9\QG9:
MW*)D)[W&RC&.MYD56ZQ@$R0"80$=MA'8-%`JD/VYJ#(=M7U,F,\'Y#Z(5&E\
MI+WAE)Z[$?=W=?RS7;'7<>RZ#AR"8JM+`SMD6JFIXCTN/A$-M%%>KV(;"(#[
M0';[&B+HW/&&IK-=;BH"#SKFO`CJ+ECRAK)@^9JD+/RI3,7+(D5+JVZH7)BY
MB4E'`.`3(@D<5DRB)^G<HD7GCWWG#WD('O;.>U/`=T#-:E/<<JZWA6,R/(U'
M#BEF0H-E/$SJ,N[;I8Y2C%[4PI\ITFV2*V4?I[]`)CTZ(O0DPI@!YBW'L]CO
M(.:<M<H4+*NY^NYKD.O1[(^=1SV);Q$E70CZO2JA7AK,@FBHJJT59J@8ZZ@"
M;H$"%(H_&?<8PPCDNR<%>V-@J-Y*95PS$';VZ-Q9^+V+N(/'<[HZWNK/)686
MS0:VC)C)KBHK!5AC,S+@Y7`"F15-42$59+N;U_E5$=__`+*4CR[O^';ADFPV
MO'T@R@\$TB=J>.L?U]/.3]%I5XJ6M\M+7*ZK`N"BZTC(&0$3J=*2*9`VT17U
MKC_!6V?]G+!_BMYHBII^BW_FY<_?Z4]<_B,IHBPQLII/E=ZQRR4"^9!R)0&N
M-HZP4/'5BQM.-ZQ;JVPHW&)W8HEM79=[&S#:.2D9:8?+N#`W.*X.E0\#*=0$
M5P^<[>K.S0DS6Y_F?SYE(*PQ,E!348YS[#>[R,1+LUH^28KBECQ-4$G;)P=,
MPD,4X`;<H@.PZ(NG^)O;4XN=GC`'*>3X;QV18Y"STN;R9-Q5\O+R]MUK/C6D
MV1Q7W$6@^:-R,E%@5$BX`!O/`I`-X$`-$5=/T6)R7V$[EF<;2[^N<J7?+&)3
M6>==F%:3>)3K;)-MD72ZZG4JH$M8I%=4XB8=U$]Q\=$5X"=@8*T1#^OV:%B+
M'`RB/N\G!ST:RF(>1;]9%/(?QDB@Y9/$043*;I4(8O4`#MN&B+'+F>U;,N%'
M*]DR;H,V3/B[F]HS9M44V[5HU;XNLB+=LV;HE(BW;H)$`A"$`"D*`````:(J
MWOHQOS7&6_Z8^0O]5^(-$4H'J)0`W9:Y\`8`$/R75X=A`!#<N2J48H^/PE,`
M"'Q#HBX'Z9S\R?PN_<K*?^N2^Z(H7.ZZBBX]5]VC4G"*+A+\3<,'\I=)-9/S
M$LAYH614\M4IB>8BL0IR&VW(<H&#80`=$5XC_E?_`&G_``M$5(ST_+%",[^O
M?28M0.5N2QY!5*4YS''K7Y%/7)S"(^T?-7-M\0#MHBNU+KH-DC+N5T6R!!(!
MUG"J:")!44*DF!E53$(45%3E*7<?$P@`>(AHBB$[N&))JQT3'^789HJ\:XZ>
M2T';2H@911C"64[%1C*G3*41!JSE&0)K''P3!<IA\`$0(H/\9WZ5Q;D&FY(@
MFK!_,4J>96&,9RA5CQKIVQ$QDD7I6RJ+@S<_5X]!RF^(=$4D/];QR",(`3'6
M)CG.8I")IL[6HHHH<P%(FFF6=$ZBBAS`4I0W$PB`!XZ(IT\-360;+BZDV'*<
M1$P%^G8-O,6&"@R.TX^'5D!,Z:1Y$WR[ET1RUCU$@<`<X]*_6'L#1%'?W@^>
M63NW?QDK.;\452D7&Q366Z[C]U%7Y*;6ADHJ7@+/+.'B!(&5B'GU@FXA$BD$
MROE@0YMRB.VJ3F;RXLK5LMKM\TR-;[U:4-?8MC_3!V<X_P![^?W'$N1W%W:V
M46-DN`^W,8>7LDB8`3(R1NVDA)]VM0-5#!P$]0MRJY9<Q<"<=;MA_`U>J>5;
MBM7IR9K#.])S[%FG!2\KYL8>3MT@P*X%:.*7]41.7I,/AOL.J';YO*.NX8IA
M#Y3Y`TT!K0^Q;5]Y_1'V[[;=K\SSC%9/,39''6HEC9*ZW,;G>8QE'AL#7$4<
M>C@5;[U>2\Q5K4_O"_-HB^]$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$3
M1$T1-$31$T1-$31$T15[_47_`,USCQ_36XF_^HO$NB*?:M_P=@/W%B_[Q0T1
M;UHB^3")2F$`$P@41`H>TP@&X`'RB.B*._B-W%,:<ILW<G..(P4UCC,_&.^.
MJQ8Z-;4VS24GZTI,6.,K][@"-WKTKVO3R-=,ND<134!-8G40!'8"*1$1`H"8
MP@4I0$3&$0````W$1$?```-$7F",,/1.;_52KL.-[%%[4JKGU&WVF2KB?1&P
MKB,@197V3=*H@4J0$N<@JDL8NXF54';???10'RJ7#ULH&#C[P\\2=(Y`R2&P
MA],1"-HN_2/3[`^?114]'IZ@'^J#X:CL/C2;-M\O_P"Q[H'A_9T13"VFTUVD
MUZ7MEMF6%?K<`Q<2<S,R:Y6S&.8-4S*N'3E8W@1-),HB/M'8-$7DA0+!QW'_
M`%"+JW\;H55_6[CRR@\DL7,4B=)LWJ%%E828FYM8R0"1LA[A75U`_"\-O$=$
M5TOU:K7W+M''9"<5!:9?H345#"(F4]WK%O2ZS".XB)NC<=$7'_2`?FLE?Y;[
M_P#WC6=%`?OJUCHHKRRN21>KU5<`&PC_`.,FK_>E*8=OKU[X_2$-MOC#Q#1%
MZEC/]AM/VLA^M%T1:G1$T1-$5??U+KIL3MI2$>HJ`/)K-N.(J+:EV%P^?N8V
MW^0U;)B(=:RG2.P>'LT4#T72/?S[#ZW<=1K/*[BO.,L:\\<+QL<6L/A79P$3
MF*,K<DC+5F$GK*4$'%>NM2=IF/`S"BATDP'W9<"I>4LW**Y=P[[Z]<H%.J^"
M^\A2K9V\^7]58H5V;G,Q5.R16#,U_4[=NS+D.B95:1\G2F:D\9,ZSQHL_%HD
ML`F;.5DE"%(19O7'O7]N")8*M\4\AJ_RIR.Y;*'JF%N)K*5Y!92N4F"(JM(B
M+K^.6,XC&'>FV+[S)+,FB>_TU0]@D53[AYVG^[?R`[U]$[M'(?BPPX_8WG.4
MY,UVFHW;(U.1N=6H_N3J+@8UM5&\K(3[R0@8))F@H1PBU<G53,;RD]]@(K@O
M=TJW(V\]M;F54N)2-@=<@+%AN=C*$QJ3I9E;Y(CETR+:8NI.6SAJY)9I.G>_
MH,024*L=RH0J?TQ+HBJY^F([G'"[BGPQG^%N7VV0*'S'A\Z9%G);%$!@[)]U
MR9F!Q-_5Z<']41M+J$R^=V*!0CC1*S*0,U,S]U(<1`BAC%(NF>]GE;D95NZO
MVK>XWRDXS6'C;Q`QEDZI5RO3TL_/>+_%4^KY2;6N8L.;H.HMY"'QU<)B#EE9
M!A6VSJ0=D9-5"'54=$413(K.BW>.XSR^!<N<A+,-KJ_'6P3ULHG$S(R>.<K3
MTURK3K^.8R4M=HI5"C*(>RQ-<1NTLXA(MT^2;MY,61UR*%3'<"*MKZ2CE'C?
MB_7.3^`^2"&0\.Y$SYGR@6+$,=;L0Y0;15P7E8=Y658QM9&E3>PL<_2E#MB"
MF^7:D`JH'`Y@Z^DBRQ[SG`'D9Q3[H/'[OI\/L567.4'0IJMO>6^(:.U!W;V$
M'4X'\39VZPD+&B67GXFT8Q77;/O(2<'CWS)-PJ4R"QQ2(IRJ1WT>TI?J#%9"
MB>=&#HUK+-&ZY:58K`K"998OW!"[UMYB5VU#(1[.BY,*'N*$>NLLL&R(*@)1
M,19)\6<LYFY,1>9KQEC#*F)<"V:R$K7'&G7J(DX7+MZQ0C`$8V/)65ZQ)K%7
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M`\IN!_/JY/N,?)+'?)BQVXN-[W4K<M8K8G-5&F50T!4(^"@Y9:PVHDY5#)MX
M]L!W#])VW5:E634$Q2*3OOP<_P#$5[[4G(#C^[JN7:GRDY"8FHC^H<:)'%=[
MG,F0<78[]!344ZNR]7@):I5=R-5A57[EJXD0=,C"#95,'`&(!%N/IG^7F$(_
MMN8"XE6:6N%(Y#89K67YN]XXNN,<CUIZSK;&_P!FMRUCCIF3JZ-;F(P8"<;J
M@5N\.Y$XF3\KK+L)%!YW'.;6',I^HEX"<S,9167KWQCXZ16(*_DK+,%@W,'U
M.S7CK?D&4L3R+C7]*93TPPKC"VMCKJ-VIP4,10J7F=/B17D)3G)Q:A>.<1RY
MDLGG;\?)YRDWB;X6CY&<+O'2TP]@DFI:<VJ*U[2<'EX]9#H4C"F`Q-Q#I$!$
MBH]=C[F5BC`7>0[FF=\Y,LNXWP[RUG<B*X:R+;,(Y=&,FUI;/(V>LM)8L=4)
M)_73S==D/.1%XBFFGY?0H=,VP"17#^[]*O8[M9<\9Z#DGL7)1W%[)DW"3$8X
M692,;(,J^I(Q4I'NDA37:/F3I)-9%0H@=-0H"&PAHBA;[(/J/N.G.#%%.XU\
MV[K2\2\MHZ/C<?G<WMRG'X\Y)-2L&D4TG8R:F0^HHZ\V$PB22A':Q/>G0BJS
M%0BODHD4PV2.U#@:ZSKNP4^Q6_&B4FN9XM!P)8J9K:!EAZQ"'9R+?SHUJ8!W
M*D18Z9=_H@`;!HBY3C'@MQ=XEHR>9K[8TY0E)CUYM[>\O2<!$4ZD,V`>\+V#
MR5TV4+&.&92"(.W*AQ2`?H=)MAT10L3GJ&<=<LN[KP@X"<&;0G;L(R65IY_G
MW.\>20:1^1W-<QW?I2+QOC\KM%L9_2&\HP;/)&5,04Y)5)))ML@0RJY%D'ZH
M'\WW0OZ2U'_B;?\`5!Y%_,F?IF?OK>S[OC^^F\_L*?\`7VRJG]EW\Z/PU_E/
M=_Q.L^K:@_GUO^G;^->CWJL_P]<I_L\?KHEZ=NLAKY]5K4_O"_-HB^]$31$T
M1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T15[_47_`,US
MCN'AX\U^)A0W'8-S<C,2`&X_`&XZ(I]ZZ`DK\$0WM+#1A1VW$-P9(`.P[>(;
MZ(-14=%O&_S_`&!^YHHT3?Y_L#]S1**(#G;VJ(_D?ENL<M^-^7K#Q5YIT>-&
M'B\Q5-!56'NM>2(R.WJ648&,=0<E;:\1:,0*1'ZQ0*1,5"^/7N!0IXK#S(O'
M?U#V8:F_P_-\L.*&-JI.-CP$WE/'V)+''7XT*Z)[L^>QO1F!99B_69G.7]$/
M4.X[Z(LNNU7V:./':^A+//UA_)Y3Y`9(,X7R=G&W)(*V&><OGYY230BA,DH^
MBXR2DA*NNDHY<&563*<3;AHE%CAZ@+M!Y:[MF-<$TS%&1JMCUYBRSVV:E5[+
M$+21)%"P-:X@@FW%.7BO+,@,.<1W$WWP:(N@^*'"#OV\,N/V-^-&(>1O#AYC
MC%D<_BZNK:L,3DG.`RD9>4G%D7CY++K%-;ID)=40$$B!MMX?#HBX?R5[2O>>
M[@\0.->67<3QQCW"DITEMU#P?C&RP+*SM/*,@NPEDARM)MWC55%50.@Y.GZ7
MCHH*4[M>=F'B'VKZV_-A>#?V/*=F9IM;GEFV^XOK/*IE*4#1T8X2CVSB*@@.
M!CD:BJMTG54'K'JV`N5%I^]MV\L@]S7A:[XVXSN$'2;*M?H"VDF+"Q4?1XM8
MF,G6*K844W\:8%%#RI1`?,]A1\-%!;/V.NW!D3M?\.!X[9.ND#>;(?(-FMPR
MU=CU&#`K2:;Q"*+;RE)"3,*B1H\VX^9X[AX:(`IE=_G^P/W-%&BIU95].GR)
MOO>6C.XTQS-166.&>>(7*BM15@G!Y\8F/D7#Q:-!V%A3)[P9-4"@?W?V_H=%
M!7$$">4@BD([BDDFF(@`^(D(!1'^SMHHT7]=_G^P/W-$HF_S_8'10HJJ(\RN
M]CREYK\VL+<+Y[BA6L7<7,C0%&9)Y1I+Z4LSM23H%%MJQUG25]@_>$P5M@[*
M`@!0Z>CVAOJ)%-"H!P<*CHN<M>VUW4.<6:<&3/='SCA'\@&`[]%Y19X?P34W
M\.VR1;X!XBI"?C6LYN]B9'8M6JCE/I.V,/2N.P_`,%%69M$6SS==KUF;%962
M!A+"S*(B5K.Q,?+MBB.V_2A(-W"9=]@]@?!HBVZO4:D5`3&J=,J56,<#%.:N
M5N&A#&*;[XIC1C)J80-\/QZ(N4[[^(^(Z(FB+8VM7K+&67GF5;K[.<==?O,T
MUA8QO+./,`0.*\DBU(\5$X"._4<=]]$6JEH:'GV1XV>B(N;CE#D4483$>TDV
M1U$Q$2*':OD5T#'((CL(EW#?1%_=%@P;MF[)NP8H,VB946C1%FV3:M4B!TD2
M;-R)`B@F4O@!2%`-$7#\BR<W5J!=;+2:8VNMR@:O-RU3IZ9D(XUHL;"/7<0T
M"$@5LN9B$I($31%8"'%(#]0%';8>FX?)%;ODA;OE:TD-]I`T'TG13V,M[6[R
M,%M?2^1922L;))2OEL+@'/II7:*FE158-67E;R#J'*?C9Q2GL>X>"T\A<298
MR:M8V=CN:\-2U\3-ZH>8K:[)6)2=3PR2]I\M%R0S8I0;F$R?T@`+?=D<PR_B
MQ[V6PEEB<^M7T&VE0=-3JL@6W$^,W?%<ERR"XO?A,?=P0;"R(.D$^_:\'<0V
M@94M->NA7&LL7TV`<65S/]RXB8"CLMN.2U&PK:%8^-BVSE6MW[-+#%L!DRI7
M$]+3GY$CZ/FFDNFU=E;CT'.D*H&(!C<[K+WUE8-NKF%@F^);$X5-*.?L#VDB
MI!J"*TT4MAN)8//Y^7%XZ]F=9C%RW3'F-NX216QG?#(T/H"US71ES2=0#372
M32.F8>;25<PTO&3+9)RLS5<Q<@UD44W3<0*NV569K+)IN41$.L@B!B_"`:N!
MDD<@K&X.%?`U_$L?S03V[@R=CV/(K1P+30]#0TT/@5LSQ[1[5#2K>0=U&S5U
M#K;SB#UQ"S<(@)"]9T9=-<[J/1$I!W$JP!X:@)HG`N:YI:.IJ*#Y_8N;[2ZC
M>V-\4C9'_5!:07?,*5/T+AU.HN!:&O*R^/J;AVF.6:959R4IE=I%=69I/4`=
M$5EG\&S9G;)O&ZH*`98Y04(;J#<!WT\Z*A.YM!UU&GS^Q#:W0<UICDW/)VC:
M:NH:&FFM#H:>*[!"R5TT82:+8(,8913R22X2\>,6=;SA;^220!Q[F97SRB3I
M`_5UAMMOH)HBSS`YOEGQJ*?AZ*'PMT)3;F.3SP*[=IW4ZUI2O35<0)5</6RT
MJ7!*M8QL]V@EDFBMI2A:G.6J&73`00;*S9&KJ7CE2`0>DAE2&#8=M19+')41
MN:XCK0@T^>BA+;7$`:9XWL#A4;FD5'M%0*CYERXDO6GSF11))U]Z\B`'ZW2*
M\C'3J+*03@(R9`4468E(*9@$5N@`Z1^+4!+$20'-);UU&GS^SZ4=;7#&M>Z-
MX:_ZI+2`[\G37Z%](2==,=C[J_@3*2B:IXSW9S&B>213`!6-'^4<3/DB!]^*
M76`?#H)8B0`YI+NFHU^;VH;>X:'%S'@,^M[I]VOMTT^E=:R.3ZA*Q65F6-)G
M&MMR%C-K*QKVLR%EC8F)C;RE76LY"URX339K)*UYJZ^M6(.URH+G:).=Q3%0
M.C4LZ^A>V5EL^-]S$#[I=0;J5`)\!J*GPJJG%AKJ&6SDRD5Q#C;HM<'B,N<Z
M+>6N?&TD;R-KMHJ-Q;UIJN70D^"5&K4W?_Q0JTB]@X-U8FK2=9OJC&V!\Q07
M?Q\+8)!O%HRT<B_,H1JY,BB=PD4#]!=Q`.YDU(&R7!8QQ`KK[H)\`32OR*4G
MM0Z^EML<)986R.#*L(>6`FA<P;MII0D5-#I5;RXDJNS^KQ=OJXT"5':*,Y<Q
M3<),>@BH?5PJG(#[]3.4WZEU?1$!]@AKF98FTW.:-W34:_-[5+LMKB3=LC>[
M9]:C2=OSZ:?2H[^\G^:E[@VWL_V4\N_Q8=Z[%TKQ12'.F8ITSF(<ABG(<AA*
M8ARB`E.4Q1`2F*(;@(>(#HBS3Q=W(>?^%(=O7<4\T.3E%KS1+R&=?@<TWYM`
ML4=@`$F,,><5C61`V]B21-M$77N9N9/+7D4D+;//)C.^8&/690L7D7*UVMD.
MD<QNHQD8:9FG<6@(B/Z!$NB*2CTX?YZS@;_*'<O]4>0M$5_#U0/YONA?TEJ/
M_$V_ZH/(OYDS],S]];V?=\?WTWG]A3_K[953^R[^='X:_P`I[O\`B=9]6U!_
M/K?].W\:]'O59_AZY3_9X_71+T[=9#7SZK6I_>%^;1%]Z(FB)HB:(FB)HB:(
MFB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HBK*^JO66;=MZ,<MU5$'#?
M.F&%VZZ)S)+(+HY7H"B2R*I!*=)5)0H&*8H@)1`!#QU2L\2W`WSFDAPLYB".
MH/EN5_=IXXYN['%H9FM?"_D>-:YI`+7--[`""#H00:$'0C0JHPSS3F$K-J4,
MJ9$`H-FY0`+G80`"E1(4H!_A#P``#;7FG-F<OYKQ\5<?6/\`XC_;\Z^WK'=M
M.W1Q\#C@</7R6'^9V_BT?Z-:G\M>8O$?RJ9$\0V'_P#,[#[/_J'RZZ_MK,?[
MU<?ZQ_\`"IS_`*9]N?\`X'#_`/L[?_9KO_%M!YUYKC'4YBQGGRZ0[/=-:5B9
MJT#'B)?$Q4'CB00;NC%^$$C'$!`0^#5RX?#\_P`]$9\2R_FA`^L'N`^@N<`?
MHJL/\]YGZ4NU]ZS&<]EXGC<C(12*6"V,FO3<QD;G-K_W@`NK+G<.2N.9YU6;
MW;,PU&P,#&3<1-@L%LC'J?2/3U`B[>)BJD(AX'+U%-\`CJCW]QR?%7!M<C)>
M0W#?XKWO!_=.H^4:*_\`C/'^R?-,2S.<3L..9'$2BK9;>WM96&OA5C#0^UIH
M1XA<ZQY`<U\KMA>8X2Y`W!BD7K]_A7UU=,!*(#XD?`Y!HKX!^A.(ZGL?:<WR
MD?FX\9"6(>+3)3\-:%6MR_,>F3@4XM>9.XCCKMQ_DYF639/I9MWCZ0%H'#;F
M,UO#3&SM?/+2^/3']QJKJ1N;69>BF0%%#LV:SA-1TF4AMQ,3J+X^W4'6O-FW
MPQKQ?B^<*AA,@)'M&NO7P4S#=^FZ?C$G-+<<3DXK'0/NFQV;H65-`'O#2&DT
MT#J'1:RF0O-'(BDNE1C9[M:L`^.PFDX.4N$@:,?IF$IVKPK=V<4%B&#82CL(
M:Y6EGS:_,@LA?RF)Q:_:Z0[7#J#KU^12_(\MZ9^(QVTO)_V3L([R(20&:*TC
M$L9U#V;F#<TCQ"W:UTCG31XPDQ<F'(2LQ3AZVCTY";D+C&M#OGBJ:#1L"[IV
MDF"KA=4I"!O](Q@#VCKLN<;SNSB\Z[;D(X=P&YSI`*F@`J3XD@?/HI#`\J]*
M_)[TX[CLW$+V_;$Z0QPQVDC]C`7/=M:PFC6@DZ:`$]%T_8,E9_JDS(U^RW[*
MD'.1;E5E)1<I:+.S>M'+=0Z2J2S==\0Y>DY1#?;8WM`1#5&NLAR"RG=;7<]U
M'<,-"USW@@CYS_VK(N'X9VCY#C(<Q@\3@;O%3L#XY8K6V>QS7`$$.:PCH1IU
M'0T*W&GW/DED*8&!I-QRY:9KW)Z^&-A++:'[P&,<V6>OG(HMWQS`BU:HG4.;
MX"E$==MC<\ER<_PUA+=RS[2=K7O)H`23U\`"I/DG'>RW#L=]K<HQW'K#&>:Q
MGF36ULQF^1P8QM7,I5SB&@>)(6SIY3SPM*C!H9"RFXF2NE8_ZJ;VBT.)$7B!
MSIK-"LT7IW!W"9TS`)0*)@$!UTMR.?=/\,R>[=<5+=H>\NJ.HH#6JJ+^#=IX
ML?\`:TV(P+,68Q)YKK:U;'L<`6O+W,#0T@@@DTU7>SK&G/UC6OQO=5WDJC72
M("Y&2.:]]!6_1Y@JF1!87()@0-]Q)[-5Y^([@1P?$OBR0A`K7\YT^:M?W%BN
M#G'I)NLS^S\%[PIV7+]OE@6-2ZM*!U-M:Z:%<>HL!S6R;'.9;'Y,_P!OC6#Y
M2.=O(*1N<@BU?IEZU6BYT71O+<)E-N8@^(;ZEK&TYMDX3/8"_EA:[:2UTA`/
MLZ]56.4YCTR\(O68[EQXECKZ:(2,9/'9QET9T#V@M%6FFA&A7QD"#YI8JB&\
M[D?\O=*AG3TC-M(V*4N$8T6?*@<R;8BSEV0HK*`0PE+[1V';4+^VYIBXA/D?
MCX87.H"YT@!/LZ]5RXEE?31SN_?B^&_LGDLC'$7NCMXK21S6"E7$-82`*BI\
M*BJYW"X7[A]BIHWZ&K/(U_4CM57H2R4A;"E5:I$ZE%T6BC\C]9/H#<!(D._P
M;ZJUOQKN3=6'VE##D#9TK7>X&GY)=N_<5G9/NIZ-\-R8<0R5_P`-BY"'AGE&
M*U(#B=`9!&8@:]:O%/%8U/LN9PBWCAA)9(R?'OV:AVSID^M5G:.VRJ1A(HBX
M;.'J:R*J9RB!BF`#`(>.K3ERF=@D,4UQ=,E::$%[P1\A!-5G&T[?]KLA;,O+
M'#8.:SE:',?':VSV.!%0YKFL(((U!!H5I0S7F(.G;*N10Z?9M<[#X?\`W#77
M]M9C_>KC_6/_`(5,'MGVY-:X'#Z_^CM_]FK!OI-I22FK)W!I.8D7LI)O,NQ"
MCM](.%GCUR<*#C-,JB[MP9198P$(!0ZC#L`!KT+[92RS<#QLLSBZ0Q.J2:D_
MG']25\='KDL++&>K+FECCH8X+*/(1!D<;0QC1\);FC6M``U).@ZJYWJ^EJDM
MOT1-$31$T1-$31$T1-$00WT10R<@[%)_UN_"ZYM,;9CEJ%BC"G(['E^R!"XF
MO4O2(&VY<''XT>.4L;"%78.T'X0KCSW2!E6K,0+YZB>X]-G7MZQG)X)#'.8H
MHGQN<(I"T.>134-H1[2-!XGK3-O'K)I[/9FS=<V++^[O;2:*)UQ"V5T<'F^8
M=A>""-PHTT<[^*#I7N/NQL'=BXR5BHL*-?L@+S?(_C9(R,#CZFV>Y2`5.D9F
MIMTO$A((U9HY=Q\7'U&%=J&5,9/S3%!%/J4.4H]_+1OQS(-CW[KB(D-:YWNM
M>'.KM!H-H/S]!JJ3V>>RVY3->OGM[=L>,O6M?-+'$/,EMI(H@#(0"XR.:*:T
M^L:`$K$V7QQE,;=W=,.\/Z%<<.N\D8;Q9)X#<,J+/8LQM.93CZ'+UK*;VAVA
MS%1M7B[A.IKQK([]$R9E7($<B8_NZBA:6(IC/E+'$1OA:^%GET8Z-A<!1^TD
M!H<:TJ.IU\%=L62Q?P7$,WS*X@O1;7L[;JLS+B9L!E:^`2QASI'1M(>[::@-
MJV@W`+M:BXIX[O<$\B9R@X9SZFYMW%%IB_(^/KOC6S0U?DYFNPDNRJU21QHM
M7H1.YY'BI.36;J2[!F^`S,I"G>F3\G7;:VV.%A<F&&Y)=:ACVOC(;4#W6AFU
MNYP)^L`=/XW14O(9;DK,_C(+^]QVV++F>&6*=CGM:]S2^0S[W>5"YK01&]S/
M>K1E=RZHIF'Z9@GMB8MMD9PVLM\RS;J?Q5I_(JIR56OGX\/+%CN9BHI[D7+-
M+C%0NN5XO$<R=S(*1B*;@\XR23;@)V73Y?$6EG9<=;-!9N?,\1"1I:_<2T_6
M>P>\\,=4TI[PH.BJEYF<AGNZ5S93YJ*WQ4$M]):2-DA\H,F:7"&WE/YJW=.V
MC0\D"-Q+M'UKCSENC2<+P1[M^,LF8UO1HG\;VW(/%[^V8K3Q_2'D7:ZIBU5C
M8L>13-<U?J%B=WF*EG9HIHJG(Q;D14?`BX6W/)"`C$Y*UNHGD;O.871[&ZAM
M"T=&N)J=HU;_`!J%7!C[^.;G7$<KBKJW$OD&TF$=QYTH=&^<.9,XC?(P1NC;
MYC@62#2/<T:9<4O'4C:.5,/;^$V-)[`%9K7$/+N/LX6J=QK/8FJEUR]9&U>-
MQYBCQ$[%1H9#L^.K$VE9-S-MDGB3)FY,@9VJ+L$PG[2`2W[9<'$ZWC;:/;(3
M&Z,.>1^;%"!N+75<7"M!XZJT\CDF6G%GV?.KJ/(W,N8MYK:-L[+B2*W87_%N
MW,<[R62L+&-B):7.`=L&RJY#V_,)8^8QV'F]\QUGF*Y,T/!UEQ-R/"[0DK&X
M\G)J>/'JY)&[V-Q$1E6S@WN%W:+2,*^3=39_+>*N`,B59?>.!L;0.9'-%<_'
MMA>R4/:1'[Q]\.<6@2!SM6ZOZUTU4OW$SV3D=>/L+G'NXQ/?QW%GY3VNF:U@
M(A\I@<Y]J8XB&2MVQ"K0W7:U8AX0@9VC5SM=8VEN/V:&E]XB<N\JU++UE;XB
MN2L1C:GW6!Y#0U=:Q=G3C!;VS'=E>V.!6%]$'?1+1%%)5THB)$P&GX\-M6X^
MWEMIA<6MP]KG>4ZC`_S``#3WFN)!);5HI4TT5XYR>#(7'*LE#DK$X_,8>"2W
M8;B+=-)$ZS<\N9NK',P,E&V0-D<20P.J5WT^Q!1Z:W[Q-*M'&J<>6/*LCD"^
MTF0@L)2=CBL@4?(F"\<P%?9URR04*[9STP_R]#O%7,4@J9ZT>I&>+IID$%M3
M!L[.V?EHY;0F9^YS'-A+@6/8V@:X`UK)KM&H-7$#JJ`S,Y"_/"[VSRD;;:T;
M%%*U]TUCHI8;F9SR]CW`L:+=S0V0C:YI#&DGW5_*N1D^T8=M>\YNQ7D:V\6*
M5Q!=XJO>.Y7%EML\AC?D\WA*+7(>V9%PXE!2-E>L30$#.P["6,Q<MXY1P*G4
MDF](L:8<X.-A=WD,LF+;;EI:8W.+):4W/CH7=`6AU"!\E:KA*^(NY+C<'>6L
M'+)LNV>.9MQ&QLUEND>Z.&YWA@(>Z*1\>]I>!34L+5HN7N(2-S<;WO'[$EW)
M'8TQ0R@JGQYR1B*T7[%V3,?R>2X9W%XW97=J]E+=QNS?'#7F\G&3RRY2-HXR
M;>1`B:)DR2N6MHG?#BTMY=C(`&Q/C<YCFF0$,W"KHI-`0XD4%`ZE**8X;F'N
M&39R&]M_-N;TNDO(;B.&>&40.#IC$0V.\M3O+'Q`:O!='4N!.=/=5HUVRGVU
M>;N/L?U69M]^NW&G)L!5Z=7VII2=G+#*UQP@SA8MJV`3/GSAR?RR%('TQ]FL
M@@DBIT*UY<`'$`U%>OM7DD!V;.ZH/C_L!\H/'X\5V$/M"WW#45!/ZFONJ?\`
MD#Y0?]UE@_Z/HB?U-?=4_P#('R@_[K+!_P!'T12\=ACMB=PK!O=MX8Y5S!PY
MS[CG&]0O5K>VFZVW'TS#UV`9NL8WB-;N9.2=(D0:I+2#U%$HF'Q44*'PZ(KK
M/J(L'9@S_P`(J52\)XWMV4+8SY`4^==5^EP[F;E6\,UJEU:N9-5HU*94C)!R
M]2(93;8IE"@/MU0>0AQLF;&N<?.;HT$FFNM!X+<KT/<MXQPSNU=93E=_:X_'
M.PTT8DG>(V%YF@(8'.H-Q#20/$`JMKVG.`O-3%?<6XI9`R-QAS+2Z16,B.7]
MBM-@I<G'0L*R/5K"U*ZD7RR8)-D!<N"$ZC#MU&`-6U:MF??6](I0!,TDEC@`
M/:20M]/4EWE[4\B['<CPN#Y!BKK+7%B&QQ1SL<][O.B.UK0:DT!.GL7H9ZR&
MO$%:U/[POS:(OO1$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1
M-$31$T1-$59'U6OYMAE_+?AS_6I0M4G/_P!07_\`P<_ZIRR#VB_O=XI_S+C/
MZ=`J9[3]BMOVNC^MEUY@S?RS_P`H_C7W78W^KK?]`S_-"U(;;AU;B'P[>W;Y
M/EUP%*BO13CJ[3M^M16S^1T)RPF^&G$ZY=LJR6&.PY4J&5QD.N87EG=?MB]Y
M1EI/ZRE9P(([%23CDQ,<BJ2ZY@$0WZ!V#6X?)H.5W?#,5<]LI'C&QP@R,@.U
MY>*[B=M*BM:@G4^"^>SLOE.P.*]2G/\`CWK?LK2;N'?Y0BPN<Q$R>T99NCC$
M<4)F#Q'*10M>R,$`TW!1=<=*MEGN?\ZJQ`\L)E1<V/:M]:Y0<N(I*"DG%*QV
MO%,)A@^/&IM533#Q!QL=R8WF'.4QC'W'?6,.-VN<[I\]B@YAJ+*'=,"P,)9%
MM!:Z@&KO$]=.JWJ[RYSMYZ&?2G?Y/T^0A@S5^8\8!,Z>-MYD&RR121^87CRF
M.'NQ@;0"`&T6]<F^[IFA.WO\=<1%V7&S!-*>GB*K`8ZC8NNRTJDP4!,9*<E(
M1FP=K*+J)B`HF56)L7?JW,(:Y<L[R9F.]=B^'!F.P=N[:QL;6@OI_&=0:?-4
MCQ\53NQGW=G;67CL7-/43YO-.ZF4B$US/?RRSQ1%XKY<,<SWM``-=X8PZTI0
M!=T=O/F;F3EOW`.)RV:'T5/6G';.TPC>Y(QD?'S\\PD4E'9"SCMDS0<2+EHF
M@FD15914XE+[0W$-5_MQSK-\SYSCOMLL?<VL$C1(&AKGASFGWJ`5H`!K7VK&
M/K&],W;7T[^DKGD?;2*XM<%FKBUG=9NEDD@@?'[A\AKWN;&UY<YQ:QK0">AI
M59A\+"YS<\;NY:AQS4L!<NFS1-C4_P`57"C6P%<F7E05,Q<(K-U2*&$2;;'#
M;Y-79Q9V=^Q>3?L[O.9.1D\O9]:NO3Y5KKZC!VKA[P=DG]XQ:_\`3EO&(!=?
M%-#H-H;%3>"'"G72BCFS1&]U^-98X7Y?.\R&Q"OE3'R#HERFGCR)4D@LT*JS
M*LDJ^6*<Z:X)F\0'Z0;ZQOFYN[L<$#.6_$#"R7,0=N`I42-(!^D!;F=LW?=^
MW5YF/_SPSCY[BQ8+(.8;1@;*(S;3!Y:=HT+2X?,:*4SN;\,<%<S,G7*JX+-&
MU/F[C2DP=PFZ8HW2C6>:*Q)Q/G@XARLE5`<3[!9!$%%%&Q#JG>;F4'Q'64>Y
M/"<#S>[EML.YD7-[6!LCHZ4\]CFZ4H=2*#WB*^\M$O1)ZENZOIHX;CL_W1;/
MD/2_F\G-:0W@<9'8>YBEH1*7@;87ASZ,;(6M$5`WHHJ>RW`35/YPV>OV2.=P
MTY`XBS8RE(YXD*3MB[:XWM@+)*ICXE.02_V=8C[+VMSC^?/M+MCH[F.VN`YI
MT((B>M^_O+\QB^3>E>RS6#FCNL3=\@PSXI&&K'L=D;6A!]A60>&8#&/";CAF
M#N'7FBU[)>7,DYQR'0./T#:6+20AZTZ9W2YLY.QNF4D@_8F=%5JR@I*E;J*D
M*KT`(`8VKMP]MB^"<?ONXM[#'<YFXOYH[9KP"(R)9`3J"*G97<!4#3H2L+=R
M,QSCU0=Y.-^COB^3O,+V[PO%L=?9Z>V>Z.6Z:^RLWQP-?&YCPRETT.87AI+=
MQ!+6K!R'[R?/>/OJ5UD<P.9Z.,N4']!DXZ.5H#Z+,J`N(D*HHV6@FK=9OND!
MB-MR%'P#X-8_A[V\\9D1>W%R)8-WO1%K1&YM=6TI05&E::+:O(_=K>DZZXB[
MC./X^+._#/S=_'+)\='*![LWQ.\3.<UU'$&2CB-2I3>(\SRMO/:WRY8N)*-F
MC\RV?DTO.N6^.G!HV1;1LBPC'TJDT]T58`T9`=00Z$]B].P;;>&LI\/NN5WO
M;"[O.)!S<S+D2X","H#BW<&_)^!:(^H;%]@^+^NOCN#]0;[.;MO8\);`'WXW
MQNDC?*R(OW!^Y^E:FIK758871+GO"Y,XYK]RY?)BW'(^9*LO-H9+DUY*MF%N
MJN4QGC9R\<(F`J)S[]11^COJU+@\^;FL6[N?YW[-B^CW>9394$]?;35;&<=;
MZ3;[@?-(?1&W#_\`60\;NA$['L#;@!P;HQP:"*G;T(\%G+W*;/W/,*9Y5SSQ
M\M]U5XM1<1&.<=M\<O';G%T-6DF@@9C:J<B+:O/E3JJ*"<56ZX&(8H";P``O
M?N7<]T,)R']H>./E=QR*,%C8R71-:*U\QGU3](=X+5ST4X/T,]SNTP[2=W\?
MC6=\KBYE;?/R#&LR4UPYP]^UO#NN&````-DCH0X@:FM8+(EYLF2[M9KY<%D%
M[-:9A_-3:K9DA&H'D7[E1RZ%)BU32;M2><H.Q"%*4H>`!K5/*9&[RV0FR5\:
MW<TA<[2FI-3H-!\R]U>&<4PG!N+6'$N-M<S!8^VCA@#GND<(XVAK:O<2YQH!
M5Q))ZU7#-2"N=63?21C_`(6Y_!N'^EJ)'IV^E_`3&OCO\6O1KM=_]`QGZ%WZ
MQZ^+OUX_XO.;_P!HP_T.V5TG5_+4=?R\DGR_9T1/))\OV=$3R2?+]G1$\DGR
M_9T1/))\OV=$3R2?+]G1$\DGR_9T1/))\OV=$3R2?+]G1%]>6`>`"?;XNH=$
M7X"10]@F#YC"&B(*91\!$PA\0F$=$3RP\!W-N'L'J'P^;1$\LN^^YM_CZAW^
MSHBZ9Y"8(J')7#MWP??9*T1M,R%&%AK(M49-K$3JT9[T@[5:-9)Y'2J;0KA5
MN4#F*EYG2&P&#?4I>V;+^V=:RN>V)XH=I`)'LJ0>OX56N/9V[XUF(,Y8LB?>
M6[MS!("YH=2E2`YM:5TUHNU8F*)$Q49%>^/I`L9'LX\KZ1414?O"LVR38'3T
M[9!JV.[<`EU*"FDF03B(@4H>&IB-GEQMCJ3M`%3U-/;TU5*GE,\SYB&M+W%U
M!6@J:T%230>%2?G6X^440V$3"`>P.H=OL:YKJ7[Y8?&?XOOA]FB+\\LH;;"8
M-O9](?#YOLZ(GEAOON;?X^H=_LZ(GEAX^)O'Q'Z0^(C\>B("1`\0Z@'XP';1
M%^]`?A'_`$PZ(G0'X1_TPZ(G0'X1_P!,.B)T!^$?],.B+\!(H>SJ#YC"&B+]
M\L!]IC_IAT1?/DD^7[.B+^@````![`T1?NB)HB:(FB)HB:(FB)HB:(FB)HB:
M(FB)HB:(FB)HB:(FB)HB:(FB)HB:(JR/JM?S;#+^6_#G^M2A:I.?_J"__P""
MG_5.60>T7][O%/\`F7&?TZ!4SVG[%;?M='];+KS!F_EG_E'\:^Z[&_U=;_H6
M?YH6L22.LJFBF'4HJ<J9"_&8X@4H?V1'7!K2]P:WJ3134DC(HW2OT8T$GYAJ
M5*O4L:]SW@--T:6QW#Y7KC;(#:*G85*BMIVR5:PMY)))5JSEOJ9LJV*=PB8.
MM$3D.!=QUF2TPW=?M_-`<:RY$-PUKFB+=)&X.H0'[*AOS$C35>?G(>>>A3U9
M8S*V?,KC`W5SB))8)G7SH;:Z@=$2'/A\YP<0TC1X:1713J91SAC3`G+3A)E+
M/U9KN/\`,O(C`DKCGDZVCS(1A(`]T:8T%M-3Q%2JK1WN2_OX_P#.3!Y?TNH?
M`=9\R'(K+`<LPM[GFPV^6R-B^&ZI0;'/$--W^2T'=J[\*\JN$=K.8=V?3]W/
MX5VEO+W+]NN'<JAR/''2!TOQ#;1V2WQ0$4$A>T0?R8][W:#4*OMS;[<7(#C3
ME291C:+9L@8RL;Y:8H>0*9!2-CA)F&D%1.W%=U"HR+1B\!8QB>2=43B7I-[#
M!K73GO;'D/'LQ(;.WFN<7*[=')&QSP0?`[0:&O[R]??2]ZT^T7>C@%J_)9:Q
MQ'.+*(17UC>3QV\T4L8H[:V9T;GLI0[@VE:CP*R<[4_'C,N&N='%RSY0H%@I
M,9D0;&]JA+)&O(E_(M(YJY:.G!6#Y!NY33(MML82[&`P"'@(:NOM%QG-8+F=
MC>9:!\$5S%)Y8<"'':0#5IH1]/58+]?W>7MKW,]+G-L%P3+6N3O<,^V9=&WD
M9+'&Z0A[6^8QSFDTZ@'0@@]%FKQR<9+C^('=">8D+;4[XGF67"%5I31Z[L8F
M!Q+"J5BBP0<.5!(/3N!2"(>&KSPTV6@XURA^%,PR0R$FWR@3)77H`"?9X+6G
MN[!P>]]0'8RV[A_`.XD[C,/G"]>QMMMVQ4WN>6M`.M*G750Y.+-SEE[!B]GG
M\_((^.?RH4113\HT);&59!_^,D25N*CB8CVS,K@3=```F`WLUAF6Z[C74UN.
M1?:1Q@N8B?.;(&`[VT)W`#K1>CUM@_2CBL3FY^T(X>WFAP=\UOV=/:/N2SX:
M4NHV&1S]M*UH*=5FMWD\F7O"W<N;9(QW./JQ<:I2,92D++,5%FZB#EK#MUD_
M^+.F<Z(G3#<O4&X?#J[^\.7R.![D1Y3&2.BO(K>$M<-.C1H?D6MOW</!>)]S
MO1/)PKF=K%?<<O\`*9*.:)X#@6NF<#U!`=0FAHI3.">7.,W.R_O>4K5!EB_F
M%1,/9%KF5Z7%BW;0^5&<O0[#%!<F**R"#M=\B>94.L4JKD2%:%$P@&XAEG@F
M:XQSR^'*6`6_+K:UDCGC!`$K71N&_I4TW'I6E%H3ZK.W7>_TJ<2;V*G?)G/3
MIEN18^YQ=Y+N=+C'Q7UO+\(\M<6-81"T-);'4R$"IH%AC2*C'=P+@MD_B#1Y
M>+:\BN-^><DW^F5!X^:M'-]A).\WU\[1CDG*J*JIFI;2F4RB7F@!R=(EW,&U
MI6EC!W$X+>\5LG,'(L=D)Y&,)`+P9I3H#X`/%3J*T'BMD.2<DO\`TA^JC`^H
M/E$$TG9OFG$\;97=VR-[FV4T=A8,:7N:"!N-LXAKMI+22#[I4'45PUY23&1$
M<6-,$90+=%I(D7]6.J38VI4ESKE;@LX<KQI$4&0'-N*QA!,"[B([`.L"0\#Y
M=/D_LEEA<B\W4UC>&_/N(I3Y>B]3+_U-=A,;PUW/;GE>#_9IL)E\QMY;N<6A
MN[:UC9"XOIT8!N)T`4U6&V7(''_9]RS`XB;W^,RE7>3[2&F&F.V4G(V-$&D=
M$)/D#)Q#5R[!!,X"4X@7;P$-]9MPL')L3VFN[/"_$MS4.1#7"$$O&C20-H)(
MIUHO,ON5>=G^9_>(<?S'<5^(FX!?<'?-$[(OBCMW;I)C&ZLSFM#CH6U/L45E
MAJG/WD!8\?8ER8TS=+N[G:6D%1X[*;&QPT*ZLKLQD6Z+9[/,6K1-T8QA#P$1
M^36+;JS[E<FNK;"9?X]YGE`C;<![6;^E:N``ZK?+#9_T@=G<+F.X?!7\7MX,
M98.FO9,6^WFF;;,%7%S('N>6Z#PHL^N%<OW3.+O)S'O'-.IY5D*BZN$'!V['
MUD@[)+XU4J4D\30L,D1\5!&-!JUAU5U2K^:9(JB7B`["&LB\)=W8XOR:WXW+
M#<R8[S0)&.#W0AAT<0^FW1M2->H6HWJ9L_09WT[(Y?O,,A@H.2MQTTUI?6\U
MO#D?BXVET$9CW&7<^4,:YFT.VN\*A8C]WJMXDJG//,<-AII$1]93&M.I5A`*
MM58=G<7U;BWEQ;M#M`!'K3LBSD%@W$2K=0#X@(:L?O/:8BSYY=18@-;'M87M
M;3:)"QI=2GC6I=\M5L=]W5FNX6?]*/'<CW(DGES!-RR%\X<)GV;+B5EHY^[6
MGPXCV=!LVTT49NL4K>-63?21_P#Q7G\&Y?\`2U$^'Z/^`F-?'V_>C\WMUZ-=
MKO[O\9^A=^L>OB[]>/\`B\YO_:,/]#ME=)U?RU'31$T1-$31$T1-$31$T1-$
M31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T
M1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$44'>EX03_/K@'E_
M"U',F7);)M$WK')%ERMTGMJHL[$W!C$"JH`HD4FE($K5,R@E3*HJ`F,4NY@Z
MIX67$#[>76*1CFGYG`@_N%5#$Y.[PF6M,W8$-O[*YBGB/LDAD;(P_0YH7FUL
M+S(T%Z_QMG2O3V)LI49TK6+57;C$/XWJE(8YH]V\CY$4%(J18NEFXJ)JH+J)
MG(8!*(AK1/GO:'DV"RTLV.@=<XN1[GM<RAV@FNTC0U%:=*:+ZQ?2?]XIV,[M
M=O,?9<NR\&$Y_96L4%U;W0>P2/B8(S/'(&NB+92W?3S-PW4+1J!O899QP40,
M6YPA3`("`@\`!`0]@@(!N`AK'XX9RL:BPN:_DE;:'U+]@2*'E>%(/^G;_`I!
ML,]YSD9@NF$H-+Y'QKBLM2B$4TM$=6;:XAC"!@`T=(62&E)!'RP./0'FB4@#
ML`````9+PO*.\.#LC86T5R^#;1N^-KBS\DD$_A)6G/<OM)]W3W3Y)^U?(KS!
MQ9E[JS.M;Z>U;-\DD<$L<9K05(:">IUJL/LH\L@S3<I/(&4<P(W*WS"YW#Z9
ME9$@JF.<YE!(W0031:,D"F-]%-%--,H>````&K'R^&Y]G;UV1RUM=S7CCJXM
M_$!0#Z`%LEP/NGZ3>V/&X>(<#S?'L;QVW:&LABF%*`4JYSMSWN/BY[G./B2L
MN,)=Y'D)@6L)4NF<BXQ[4VP#[E"6V.K5P08FZ0`HM7%EAI5ZD!!*`@4%.D!#
MP#5Z8/DG=_`6S;*UCN7VC>C9(VOII3JX%VGSK73N?VM^[O[L9M_)>17N#@Y!
M*1OGM+Z>T<^AK[S;>6.,UU!.VIKU7"KAW5LUWK+M8SC8>1K=SD2DHNFU0E46
MM=:,ZZU>$(FX;1T,TAT(<B:A4R[]2!A$0WWWU+7&:[N7.9BSTD=S]H0`B,^4
MRC`>M&[=OAX@JYN/<7^[_P",=N[[M=BKS`-X?DW,==QNO9W/N',KM=),Z4S5
M%3T>!\BVW$?=`R]@HUM-B[D.SK)KU+J3MKZ65;D23,JL<RBKMPC*P[U$AU#F
M$1!,I"^/LUTXG)]V<')<2XV.YC?=2F23\TP[GDU)HYII7V"@4[W"PWH'[IQ8
MV'G-[@;V/$6HM[3_`,]<1F&%HHUC3%*PF@\7$GY5ON4^[)G/--8;4[)/(N)L
M-<:3$?/-X\8*EQWE2L6Z;O6+LKF+KK)V!D'+5,P!U](]/B`AOJ9R^=[O9RS-
MADH[F2U+VNIY,8U:0X:M:#H0/%4K@7#/N^.V>>/)N%WF$M,TZWD@,GVC=R5B
ME8Z.1NV6=[/>:]PKMKKH5T!F/F(KGVY*W_+.6HRW6Q:/CXI26=G8-53,(M`&
MS%#RF#5HWV01#8!Z.H?A$=6QGL9S_DM]]HYBUN9;K8UM?+`]UHH![H`Z+,/;
M3N-Z2NT/&AQ'M]GL'C\`)Y)?*;<N>/,E=N>ZLCGN]YVM*T'@`MKQCRK:8<M\
M?>L;Y695>S1Q'**$@P>I")VKULJS>M'*"R2K9RV=M%SIG(H0P;&\-AV'75A<
M/SSC^09DL5:W45TRNH9U!%""#H002-5.\][K^E3N;QN;B?-L_@;["3%KBQ\_
M1['!['M<VCFN8]K7`M(U&NFB_M`\LDJID)QE.IY;0K-Z<S,A/*3T))^X.!D)
M1XJ_>F$B!2H'06<K"843$%+V?1\`U&#$<^M,H[,6=M=PW[Y'/+FM(U<2XZ="
M*GH11<,KW3]*&?X;'P'D&<X]?<6CM8[<0SRM>/+B8(V4)]X.#6@;P0[KKJ5G
MX_[\?+*0KBT`IR3K23APR/'KV-O4<?HV11JHF9)0GUNG5BNR*'(8?I@8#@/B
M`[ZR&_G'>E]J;?RIA(:_G!!'OH?"NU:C6OIS^[.M<TW+-NL4ZW:\/%L[*7KK
M8.!J#Y1N-I^8BE-*470&(>ZCFG!,+.U[&'(UK7HBS3[FT3K15E6IDLC//-O>
M9%8TW#2)P65V#<"B!0^``U0<-E^[>`@?;XR.Z9')(9'5B8ZKSU)+FG^!9:[B
M\;^[_P"ZN3M,OSB[P%WD+&S;:P.%[/#Y=NSZL;1#+&*#Y03[2OC+O=-S/G.-
M@8K)/(QK+M:Q,M[#`G8,JU7'T9--.L6\@UDZY#14BDLF*@B&RO3N/L\`U#,Y
M;NYGHXH\DRZ<(9`]A$3&%KAT(+&M/T=%S[=\>]`/:R]N[[A=W@+>:_M76\XD
MO9[B.6%]-S'1W$LL9!H/XM?E7=9^^5RI4Q^;'BG)J*.Q/%+0AIP8.G!:?JI=
M,Z2C4MA+7@E2"**IR^854%0ZA$#;ZK?[:]Z?@/@=EQ]4MW^2S?0BE*[?9X]5
MC%O8/[M1O+QR]MQA1.)VS"W^T+GX7S6G<'^1Y_EG4`[2W9H!MHHXI/-E(FI!
MY+2^0(V2DY%RL\?/WLD9PZ=NG"AE5UUUE>I11150XB(B/B(ZQ?<<3YA=3.N+
MBSNGSO<2YQ:223U*W5Q_J(].N*LHL=C>38*"PA8UD<;)6M:QK11K6@"@``HN
M+369JHV;BA5@DK]970E;PU6ID1*V"7EGZP]#5H@A&LUP(*RQ@+N<Q`\?;[=5
M_C/:GE_(;]EL;62"U+O?DDHT-'B:5J=/8"L3=ZO7WZ<.SO$;G/R9ZURF89$3
M;V=IOEEGDI[C`YK?+8"Z@+I'L`KU&I%P_L]\8N3/;`[<=\Y-6JC0+K/W(;*]
M?O%GQW;EWAAJ]*LTK4\<5V..6OND4R2B+=JVD52^>IT)'$IAZP$@;\X3%08/
M$V^)MOY&",-'RGJ3]+B2OD9[J=PLOW7[B9?N+G:#)Y6\=,X``4;0,C;0:5;$
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M,7?]JH'_`!B777-_)#YUVX_^LC^C_>*](WEA_H)LW[I4C^.];U*JXU%I@3^?
,;-_NV_\`\;!HB__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
